PGT is performed before embryo implantation as part of the IVF process, allowing for early-stage analysis of the embryo’s genetic material. In contrast, traditional prenatal screening takes place during pregnancy through blood and ultrasound tests. PGT offers the advantage of selecting genetically healthy embryos in advance, increasing the chances of a successful pregnancy and reducing the risk of genetic disorders.
Yes, PGT is considered completely safe when performed by trained specialists. The embryo biopsy takes place at the blastocyst stage, involving the removal of a few cells from the outer layer (trophectoderm), without affecting embryonic development. At Fertulity, we follow certified bioethics and micromanipulation protocols to ensure the embryo’s integrity and viability.
PGT can detect a wide range of chromosomal and single-gene disorders. These include Down syndrome, Rett syndrome, cystic fibrosis, beta-thalassemia, Duchenne muscular dystrophy, and Huntington’s disease. It can also identify balanced translocations or structural chromosome abnormalities. At Fertulity, the testing process is tailored to each couple’s needs based on their medical history and genetic evaluation.